» Articles » PMID: 19241443

Alternatively Activated RAW264.7 Macrophages Enhance Tumor Lymphangiogenesis in Mouse Lung Adenocarcinoma

Overview
Journal J Cell Biochem
Date 2009 Feb 26
PMID 19241443
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-associated macrophages (TAMs) have been implicated in promoting tumor progression and invasion. The onset and maintenance of tumor angiogenesis and lymphangiogenesis also seem to be partly driven by a group of polarized alternatively activated macrophages (aaMphi) in lung adenocarcinoma. Here, the aaMphi and classically activated macrophages (caMphi) were obtained using RAW264.7 cells via IL-4 and IFN-gamma + LPS treatment, respectively. Co-inoculation of aaMphi with Lewis lung carcinoma (LLC) cells promoted tumor growth, increased lymph node metastasis, and reduced the survival in C57BL/6 mice bearing LLC. Furthermore, the effects of the activated macrophages on the lymphangiogenesis-related properties of lymphatic endothelial cells (LECs) were investigated in vitro. When LECs were cultured in macrophages conditioned medium or in a co-culture system of macrophages and LECs, aaMphi significantly promoted proliferation, migration, and tube-like formation of LECs. We identified high VEGF-C expression in aaMphi and low expression in caMphi as well as unactivated macrophages by ELISA and Western blotting. In LECs, co-culture with aaMphi resulted in a significant increase of mRNA levels of specific lymphatic marker VEGF receptor-3 and the homeobox gene Prox-1, as well as lymphangiogenic factor VEGF-C rather than VEGF-D by quantitative RT-PCR. Furthermore, enhanced LECs migration and capillary formation by co-culture with aaMphi were significantly inhibited by rVEGF receptor-3/Fc chimera. In conclusion, these data show that aaMphi play a critical role in tumor-induced lymphangiogenesis through up-regulating VEGF-C and increasing lymphangiogenesis-related behavior of LECs, which may contribute to lymphatic invasion in lung adenocarcinoma.

Citing Articles

M1 macrophages as promising agents for cell therapy of endometriosis.

Artemova D, Vishnyakova P, Elchaninov A, Gantsova E, Sukhikh G, Fatkhudinov T Heliyon. 2024; 10(16):e36340.

PMID: 39253270 PMC: 11381802. DOI: 10.1016/j.heliyon.2024.e36340.


PPAR-γ/NF-kB/AQP3 axis in M2 macrophage orchestrates lung adenocarcinoma progression by upregulating IL-6.

Lin G, Lin L, Chen X, Chen L, Yang J, Chen Y Cell Death Dis. 2024; 15(7):532.

PMID: 39060229 PMC: 11282095. DOI: 10.1038/s41419-024-06919-9.


Advantages and disadvantages of treatment of experimental ARDS by M2-polarized RAW 264.7 macrophages.

Kosyreva A, Vishnyakova P, Tsvetkov I, Kiseleva V, Dzhalilova D, Miroshnichenko E Heliyon. 2023; 9(11):e21880.

PMID: 38027880 PMC: 10658332. DOI: 10.1016/j.heliyon.2023.e21880.


Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p.

Vadevoo S, Gunassekaran G, Yoo J, Kwon T, Hur K, Chae S Front Immunol. 2022; 13:976196.

PMID: 36483544 PMC: 9724234. DOI: 10.3389/fimmu.2022.976196.


Th2 Cytokines IL-4, IL-13, and IL-10 Promote Differentiation of Pro-Lymphatic Progenitors Derived from Bone Marrow Myeloid Precursors.

Espinosa Gonzalez M, Volk-Draper L, Bhattarai N, Wilber A, Ran S Stem Cells Dev. 2022; 31(11-12):322-333.

PMID: 35442077 PMC: 9232236. DOI: 10.1089/scd.2022.0004.